Flubendazole

DB08974ApprovedInvestigationalWithdrawnSmall moleculeAnthelmintics Antiparasitic Agents

Flubendazole is an anthelmintic that is used to treat worm infection in humans. It is available OTC in Europe.

Mechanism: Flubendazole is a benzimidazole that inhibits microtubule function by binding tubulin and inhibiting tubulin polymerization. It binds to the colchicine-binding site of the tubulin protein, located at the interface of the alpha (α) and beta (β) tubulin heterodimer.
Curator reviewed · 3 references
Formula / weight: C₁₆H₁₂FN₃O₃ · 313.2832 g/mol (avg)
Code names: R-17,889

Resolves to

Compound

UNIIR8M46911LRCAS31430-15-6ChEMBLCHEMBL1454946ChEBI77095PubChem35802KEGGD04200

Clinical / RWD

RxNorm25096ATCP02CA05

Structure

InChIKeyCPEUVMUXAHMANV-UHFFFAOYSA-NSMILESCOC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C1=CC=C(F)C=C1

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Drug interactionStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

34Marketed productsAcross 2 countries and 21 labellers

1ATC codeIncluding every combination product, plus 10 drug categories

4+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Flubendazole, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In